Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesRisedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy
Urology, 07/06/09
Izumi K et al. - In a study to determine the effectiveness of risedronate against bone loss in pts with prostate cancer (PCa) receiving androgen-deprivation therapy (ADT), it was found that oral administration of risedronate is effective for recovery of ADT-induced bone loss in pts with PCa.
Methods- 60 Japanese pts with PCa who were receiving ADT or were newly scheduled for ADT were enrolled.
- Lumbar spine bone mineral density (BMD) was determined by dual-energy X-ray absorptiometry.
- Pts with a BMD <90% of the young adult mean received risedronate.
- 29 and 27 pts in the risedronate and control groups were analyzed, respectively.
- BMD, urinary deoxypyridinoline, and serum bone alkaline phosphatase were measured as bone turnover markers at 6 and 12 mos.
- BMD/young adult mean ratio correlated inversely with duration of ADT.
- Initial mean BMD was significantly lower in the risedronate group than in the control group (1.02 ± 0.19 vs 1.19 ± 0.16 g/cm2).
- The focus was pts treated with ADT for >6 mos.
- Mean percentage of changes in the BMD/young adult mean ratio of the risedronate and control groups was +2.6 ± 4.5% and ?2.8 ± 2.6% after 1 yr, respectively.
- Urinary deoxypyridinoline and bone alkaline phosphatase in the risedronate group decreased significantly after 12 mos vs levels in the controls.
Related Articles
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150mg and risedronate 150mg
Current Medical Research and Opinion, 10/23/09
Relevance Score: 88%
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/12/09
Relevance Score: 87%
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body
Bone, 10/27/09
Relevance Score: 87%
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis
Value in Health, 10/29/09
Relevance Score: 83%
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
Osteoporosis International, 10/30/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and Tolerability of Fesoterodine in Men With Overactive Bladder: A Pooled Analysis of 2 Phase III Studies
Urology, 12/07/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/07/09
Today in Endocrine...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogenic mycotoxin exposures and precocious pubertal development
International Journal of Andrology, 12/03/09
Kisspeptin/GPR54 system as potential target for endocrine disruption of reproductive development and function
International Journal of Andrology, 11/13/09
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
The Aging Male, 11/13/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era
Expert Review of Anticancer Therapy, 12/07/09
Role and rationale of gene therapy and other novel therapies in the management of NMIBC
Expert Review of Anticancer Therapy, 12/07/09
Organ-sparing strategies in the management of invasive bladder cancer
Expert Review of Anticancer Therapy, 12/07/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/07/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/07/09
Preoperative Criteria to Select Patients for Bilateral Nerve-sparing Robotic-assisted Radical Prostatectomy
The Journal of Sexual Medicine, 12/07/09
Article Search
Sponsor